Mississauga, ON, April 18, 2024 – Bayer is recalling two lots of hydraSense® Baby Nasal Care Easydose® due to a potential contamination.
Lots containing the following codes are impacted: G238402 and G239889.
No other hydraSense® products are impacted.
The safety of Canadians and the quality of our products remains our highest priority. We are working closely with Health Canada and our Canadian retail partners to ensure that all consumers are notified immediately, and that all impacted inventory is removed from shelves and quarantined as soon as possible.
What should consumers do?
While no adverse events have been reported at this time, consumers who believe that their hydraSense® Baby Nasal Care Easydose® product is from an affected lot are to stop using it immediately and to return it for a full refund by completing a form at www.hydrasense.ca/en/easydoserecall or by calling 1-800-265-7382.
If you have a medical concern, please speak with your health care provider.
How to identify if your product is part of the recall?
Lot numbers for hydraSense® Baby Nasal Care Easydose® can be found on the bottom of the box containing the single use vials and on the label of each single use vial.
For more information:
To report an adverse event, product complaint or have questions about this recall, please contact Bayer at 1-800-265-7382.
About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability, and quality throughout the world. In fiscal 2023, the Group employed around 100,000 people and had sales of 47.6 billion euros. R&D expenses before special items amounted to 5.8 billion euros. For more information, go to www.bayer.ca.
Contact for media inquiries:
Communications Department
Bayer Inc.
mediacanada@bayer.com
Find more information at www.bayer.ca
xx (2024-0XXXE)
Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.